title: Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
abstract: BACKGROUND
  Tyrosine kinase inhibitors (TKIs) drastically changed the outcome of patients affected by chronic myeloid leukemia, allowing long-term improved overall survival and deep molecular responses.
  
  
  METHODS
  In this review, all the related and "off target" side effects of different TKIs are reported and reviewed including their pathogenesis, and associated predisposing factors are discussed.
  
  
  CONCLUSIONS
  Appropriate identification of adverse events and classification according to CTC scale is required during therapy with TKI, considering the impact on the long-term quality of life. Specific evaluation and stratification of comorbidities and cardiovascular risk profile at baseline is suggested in order to better tailor individualized treatment strategy and identify patients who require strict monitoring of risk factors during treatment.
authors.affiliation: a Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.affiliation: a Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.
authors.forename: Gioia
authors.initials: G
authors.lastname: Colafigli
authors.affiliation: a Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.
authors.forename: Matteo
authors.initials: M
authors.lastname: Molica
authors.affiliation: a Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000209:etiology; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011788:Quality of Life; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases
keywords: chronic myeloid leukemia; outcome; safety; tyrosine kinase inhibitors